摘要
目的对该院临床分离的产超广谱β-内酰胺酶(ESBLs)大肠埃希菌(ECO)与非产ESBLs ECO耐药性及多位点序列分型(MLST)结果进行分析,为感染性疾病的治疗提供理论依据。方法收集89株非重复ECO,其中产ESBLs ECO 48株,非产ESBLs ECO 41株;采用BD phoenix M50全自动细菌鉴定仪进行细菌鉴定与药敏试验;89株ECO进行MLST分析,所得数据与数据库比对,获得对应等位基因序列分型(ST)。结果产ESBLs ECO耐药率显著高于非产ESBLs ECO(P<0.05);89株ECO共获得45种ST,其中产ESBLs ECO 24种,9株为ST131型,6株为ST1193型,其他型别散在分布。非产ESBLs ECO获得21种ST,其中7株为ST95型,4株为ST69型,其他型别散在分布。结论89株ECO中,产ESBLs ECO以ST131型和ST1193型为主,非产ESBLs ECO以ST95型、ST69型为主,产ESBLs和非产ESBLs ECO菌株之间存在明显ST差异;MLST对于流行病学研究具有重要意义。
Objective To analyze the drug resistance and multilocus sequence typing(MLST)results of ESBLs-producing Escherichia coli(ECO)and non-ESBLs-producing ECO clinically isolated from this hospital to provide a theoretical basis for the treatment of infectious diseases.Methods Eighty-nine strains of non-repetitive ECO were collected,including 48 strains of ESBLs-producing ECO and 41 strains of non-ESBLs-producing ECO;the BD phoenix M50 automatic bacterial identification instrument was used for conducting the bacterial identification and drug sensitivity test;89 strains of ECO conducted the MLST analysis,and the obtained data were compared with the database to get the sequence type(ST)of corresponding allele.Results The resistance rate of ESBLs-producing ECO was significantly higher than that of non-ESBLs-producing ECO;eighty-nine strains of ECO obtained the 45 kinds of ST,there were 24 kinds of ESBLs-producing ECO,9 strains were ST131 type,6 strains were ST1193 type,the other types were sporadically distributed;in non-ESBLs-producing ECO,21 kinds of ST obtained,in which 7 strains were ST95 type,4 strains were ST69,the other types were sporadically distributed.Conclusion Among 89 strains of ECO,the main ESBLs-producing ECO are ST131 type and ST1193 type.There are significant the ST difference between the the main ESBLs-producing ECO strains and non-ESBLs-producing ECO strains.MLST is of great significance to the epidemiological research.
作者
麦杏连
刘思瑶
肖婷婷
邓淑妃
何倩君
张中文
温伟洪
徐令清
MAI Xinglian;LIU Siyao;XIAO Tingting;DENG Shufei;HE Qianjun;ZHANG Zhongwen;WEN Weihong;XU Lingqing(Department of Pharmacy,Sixth Affiliated Hospital of Guangzhou Medical University/Qingyuan Municipal People′s Hospital,Qingyuan,Guangdong 511518,China;Department of Clinical Laboratory,Sixth Affiliated Hospital of Guangzhou Medical University/Qingyuan Municipal People′s Hospital,Qingyuan,Guangdong 511518,China)
出处
《检验医学与临床》
CAS
2021年第22期3217-3220,3224,共5页
Laboratory Medicine and Clinic
基金
广东省中医药局基金项目(20201407)
广东省科技创新战略专项资金(DZXQY002)
广东省医学科学技术研究基金项目(A2021490)
广东省清远市人民医院医学科研基金支持项目(20190209)。